JP2005519048A - ＧｌｙＴ１トランスポーター阻害剤ならびに神経病学および神経精神病学的障害の治療におけるその使用 - Google Patents

ＧｌｙＴ１トランスポーター阻害剤ならびに神経病学および神経精神病学的障害の治療におけるその使用 Download PDF

Info

Publication number
JP2005519048A
JP2005519048A JP2003556056A JP2003556056A JP2005519048A JP 2005519048 A JP2005519048 A JP 2005519048A JP 2003556056 A JP2003556056 A JP 2003556056A JP 2003556056 A JP2003556056 A JP 2003556056A JP 2005519048 A JP2005519048 A JP 2005519048A
Authority
JP
Japan
Prior art keywords
hydroxy
propyl
dimethyl
sulfonic acid
amide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003556056A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005519048A5 (https=
Inventor
スティーブン・クールトン
マイケル・スチュアート・ハッドリー
ヒュー・ジョナサン・ハードン
ジン・ジャン
グレアム・ジェイ・ジョイナー
ロデリック・アラン・ポーター
シャーザド・シャルーク・ラーマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of JP2005519048A publication Critical patent/JP2005519048A/ja
Publication of JP2005519048A5 publication Critical patent/JP2005519048A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
JP2003556056A 2001-12-21 2002-12-19 ＧｌｙＴ１トランスポーター阻害剤ならびに神経病学および神経精神病学的障害の治療におけるその使用 Pending JP2005519048A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0130696.8A GB0130696D0 (en) 2001-12-21 2001-12-21 Chemical Compounds
PCT/GB2002/005819 WO2003055478A1 (en) 2001-12-21 2002-12-19 Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders

Publications (2)

Publication Number Publication Date
JP2005519048A true JP2005519048A (ja) 2005-06-30
JP2005519048A5 JP2005519048A5 (https=) 2006-01-05

Family

ID=9928203

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003556056A Pending JP2005519048A (ja) 2001-12-21 2002-12-19 ＧｌｙＴ１トランスポーター阻害剤ならびに神経病学および神経精神病学的障害の治療におけるその使用

Country Status (8)

Country Link
US (1) US20050267152A1 (https=)
EP (1) EP1455777B1 (https=)
JP (1) JP2005519048A (https=)
AU (1) AU2002352483A1 (https=)
DE (1) DE60223715T2 (https=)
ES (1) ES2297030T3 (https=)
GB (1) GB0130696D0 (https=)
WO (1) WO2003055478A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008525399A (ja) * 2004-12-23 2008-07-17 グラクソ グループ リミテッド グリシン輸送阻害剤
JP2008525402A (ja) * 2004-12-23 2008-07-17 グラクソ グループ リミテッド ２−アミノ−１−フェニルエチルカルボキサミド誘導体
JP2008525398A (ja) * 2004-12-23 2008-07-17 グラクソ グループ リミテッド グリシン輸送阻害剤
WO2020129877A1 (ja) * 2018-12-18 2020-06-25 株式会社デ・ウエスタン・セラピテクス研究所 イソキノリンスルホニルクロリド酸付加塩及びその製造方法

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0314479D0 (en) * 2003-06-20 2003-07-23 Glaxo Group Ltd Compounds
GB0314478D0 (en) * 2003-06-20 2003-07-23 Glaxo Group Ltd Compounds
KR20060095865A (ko) * 2003-10-14 2006-09-04 화이자 프로덕츠 인크. 글리신 수송 억제제로서의 비시클릭 [3.1.0] 유도체
GB0326840D0 (en) * 2003-11-18 2003-12-24 Glaxo Group Ltd Compounds
GB0329362D0 (en) * 2003-12-18 2004-01-21 Glaxo Group Ltd Compounds
GB0408772D0 (en) * 2004-04-20 2004-05-26 Glaxo Group Ltd Compounds
GB0408777D0 (en) * 2004-04-20 2004-05-26 Glaxo Group Ltd Compounds
JP4646984B2 (ja) * 2004-09-30 2011-03-09 メルク・シャープ・エンド・ドーム・コーポレイション シクロプロピルピペリジングリシン輸送体阻害剤
GB0428232D0 (en) * 2004-12-23 2005-01-26 Glaxo Group Ltd Compounds
PE20061156A1 (es) * 2004-12-23 2006-12-16 Glaxo Group Ltd Derivados de benzamida como agentes inhibidores del transportador de glicina
JP2009503006A (ja) * 2005-08-02 2009-01-29 グラクソ グループ リミテッド ＧｌｙＴ１トランスポーター阻害剤ならびに神経および神経精神障害の治療におけるその使用
WO2007104775A1 (en) 2006-03-16 2007-09-20 Glaxo Group Limited Compounds which inhibit the glycine transporter and uses thereof
GB0612420D0 (en) * 2006-06-22 2006-08-02 Glaxo Group Ltd Compounds
GB0612425D0 (en) * 2006-06-22 2006-08-02 Glaxo Group Ltd Compounds
MX2009014235A (es) 2007-08-22 2010-04-27 Abbott Gmbh & Co Kg 4-bencilaminoquinolonas, composiciones farmaceuticas que las contiene y su uso.
MX2010010773A (es) 2008-04-01 2011-04-11 Abbott Gmbh & Co Kg Tetrahidroisoquinolinas, composiciones farmaceuticas que las contienen y su uso en terapia.
RU2502730C2 (ru) 2008-06-05 2013-12-27 Асахи Касеи Фарма Корпорейшн Сульфонамидные соединения и их применение
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
AR075442A1 (es) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
WO2011012622A1 (en) 2009-07-30 2011-02-03 Glaxo Group Limited Benzoxazinone derivatives for the treatment of glytl mediated disorders
WO2011023753A1 (en) 2009-08-27 2011-03-03 Glaxo Group Limited Benzoxazine derivatives as glycine transport inhibitors
CN101781244B (zh) * 2010-02-10 2014-04-16 中国农业大学 化合物4-溴-n-(吡啶-2-甲基)萘-1-磺酰胺的制备方法
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
CA2844275A1 (en) 2011-08-05 2013-02-14 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
MX2014006004A (es) 2011-11-18 2015-04-16 Abbvie Deutschland Derivados de aminobenzociclohepteno, aminotetralina, aminoindano y fenalcilamina n-sustituidas, composiciones farmaceuticas que los contienen, y su uso en terapia.
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
MX2016004934A (es) 2013-10-17 2016-12-20 Abbvie Deutschland Derivados de aminotetralina y aminoindano, composiciones farmaceuticas que los contienen, y su uso en terapia.
CA2924689A1 (en) 2013-10-17 2015-04-23 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2016123576A1 (en) * 2015-01-30 2016-08-04 Lieber Institute For Brain Development Comt inhibiting methods and compositions
WO2017091818A1 (en) 2015-11-25 2017-06-01 Lieber Institute For Brain Development Comt inhibiting methods and compositions
US12577211B2 (en) 2020-06-29 2026-03-17 Bacainn Biotherapeutics, Ltd. Probenecid compounds for the treatment of inflammasome-mediated lung disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0076072B1 (en) * 1981-09-24 1987-05-13 BEECHAM - WUELFING GmbH & Co. KG Sulphonamides
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
DE69830045T2 (de) * 1997-10-31 2006-01-12 Daiichi Suntory Pharma Co., Ltd. Arylpiperidinopropanol und Arylpiperazinopropanol Derivate und dieselbe ent- haltende Pharmazeutika
WO1999034790A1 (en) * 1998-01-09 1999-07-15 Allelix Neuroscience, Inc. Glycine transport inhibitors

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008525399A (ja) * 2004-12-23 2008-07-17 グラクソ グループ リミテッド グリシン輸送阻害剤
JP2008525402A (ja) * 2004-12-23 2008-07-17 グラクソ グループ リミテッド ２−アミノ−１−フェニルエチルカルボキサミド誘導体
JP2008525398A (ja) * 2004-12-23 2008-07-17 グラクソ グループ リミテッド グリシン輸送阻害剤
WO2020129877A1 (ja) * 2018-12-18 2020-06-25 株式会社デ・ウエスタン・セラピテクス研究所 イソキノリンスルホニルクロリド酸付加塩及びその製造方法
JPWO2020129877A1 (ja) * 2018-12-18 2021-10-28 株式会社デ・ウエスタン・セラピテクス研究所 イソキノリンスルホニルクロリド酸付加塩及びその製造方法
US11535595B2 (en) 2018-12-18 2022-12-27 D. Western Therapeutics Institute, Inc. Isoquinoline sulfonyl chloride acid addition salts and method of manufacture thereof
JP7792670B2 (ja) 2018-12-18 2025-12-26 株式会社デ・ウエスタン・セラピテクス研究所 イソキノリンスルホニルクロリド酸付加塩及びその製造方法

Also Published As

Publication number Publication date
GB0130696D0 (en) 2002-02-06
US20050267152A1 (en) 2005-12-01
DE60223715D1 (de) 2008-01-03
EP1455777B1 (en) 2007-11-21
AU2002352483A1 (en) 2003-07-15
WO2003055478A1 (en) 2003-07-10
ES2297030T3 (es) 2008-05-01
EP1455777A1 (en) 2004-09-15
DE60223715T2 (de) 2008-10-30

Similar Documents

Publication Publication Date Title
JP2005519048A (ja) ＧｌｙＴ１トランスポーター阻害剤ならびに神経病学および神経精神病学的障害の治療におけるその使用
CN109715613B (zh) 杂环化合物
CN110546151B (zh) 凋亡诱导剂
CN1678317B (zh) 用作治疗呕吐、抑郁症、焦虑症和咳嗽的神经激肽-1(nk-1)拮抗剂的1-酰氨基-4-苯基-4-苄氧基甲基-哌啶衍生物和相关化合物
CA3133753A1 (en) Novel small molecule inhibitors of tead transcription factors
US20100120740A1 (en) Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
US20030232832A1 (en) Pyrrolotriazinone compounds and their use to teat diseases
KR20140040774A (ko) 이미다조피리딘 화합물
JP2018530571A (ja) ヒストン脱アセチル化酵素６阻害剤としてのオキサジアゾールアミン誘導体化合物及びこれを含有する薬剤学的組成物
AU2002316235A2 (en) HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
WO2003013506A1 (en) Sulphonamides for control of beta-amyloid production
BRPI0308696B1 (pt) Composto derivado de quinolina, seu processo de preparação, sua composição farmacêutica e seus usos
JP2011157358A (ja) グリシン輸送阻害薬としての二環式［３．１．０］誘導体
JP2016510033A (ja) 強力なｒｏｃｋ１およびｒｏｃｋ２阻害剤としてのフェニルピラゾール誘導体
WO2004113301A1 (en) Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
WO2004113280A1 (en) Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
US20080200454A1 (en) Carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin s
TW202233620A (zh) Cftr調節劑化合物、組合物及其用途
US20210122757A1 (en) Spirocyclic compounds as modulators of indoleamine 2,3-dioxygenase
WO2004112787A1 (en) Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
CN119156375A (zh) 双环杂环衍生物和相关用途
CN108463222A (zh) 用于治疗疾病的杂环化合物
CN1321115C (zh) 作为哮喘治疗中的ccr－3受体拮抗剂的哌嗪衍生物
JP4762250B2 (ja) フェニル−ピペラジンメタノン誘導体
JP2010534639A (ja) １，２，３，４−テトラヒドロピロロ［１，２−ａ］ピラジン−６−カルボキサミド誘導体および２，３，４，５−テトラヒドロピロロ［１，２−ａ］［１，４］−ジアゼピン−７−カルボキサミド誘導体、これらの調製および治療的使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080916

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090303